Joint Transnational Call 2026 - Treatments and Adherence to Treatment Protocols (EUP OHAMR - New Treatments to Tackle Antimicrobial Resistance)

The Joint Transnational Call 2026 under the EUP OHAMR (One Health Antimicrobial Resistance) partnership is a major international funding opportunity that supports collaborative research and innovation projects focused on developing new treatments and improving adherence to treatment protocols to tackle antimicrobial resistance (AMR). The call, titled “Treatments and adherence to treatment protocols”, brings together 37 funding organisations from 28 countries and has an estimated total budget of more than €31 million for projects of up to 3 years.

The call recognises that drug‑resistant bacterial and fungal infections are causing increasing treatment failures, higher mortality and reduced productivity in human, animal and plant health. One of the main drivers of AMR is inappropriate antimicrobial use, including incorrect prescribing, overuse and poor adherence to treatment instructions. This funding opportunity therefore aims both to create new or improved treatment strategies and to change how treatments are prescribed, used and followed in real‑world One Health settings (human, animal, plant, environment).

Only transnational research and innovation projects are eligible. Each consortium must include partners from multiple participating countries, and each participating organisation is funded by its own national or regional funding agency according to specific national rules. Proposals must be submitted centrally via the EUP OHAMR submission platform using the official pre‑proposal and full‑proposal templates. In many cases, partners must also submit additional documents to their national funder’s online system, and all applicants must comply with both the joint call rules and national eligibility requirements.

The call has three main scientific and implementation topics, and proposals must address exactly one of them:

• Topic 1 focuses on identifying and developing new combination treatments using existing or innovative antimicrobials and/or adjunctive therapies to extend drug efficacy and reduce resistance. This includes combining different antibiotics or antifungals, or combining an antimicrobial with a non‑antimicrobial treatment that enhances activity or better targets the infection site. Projects can also improve existing combinations by optimising pharmacokinetics, pharmacodynamics and administration routes. For human health, proposed combinations must be directed against pathogens on the WHO priority lists for bacterial and fungal threats.
• Topic 2 focuses on developing tools and methods to improve adherence to treatment protocols. Projects can explore why people and other end‑users (such as patients, farmers, animal owners or plant producers) do not follow existing treatment instructions, and they can develop and test innovative tools such as digital solutions, behavioural and sociological interventions, reminder systems, or education programmes. Engagement with end‑users is mandatory and vulnerable groups with reduced access to conventional health and care services are expected to be considered.
• Topic 3 focuses on assessing the impact of antimicrobials used in veterinary medicine and agriculture on the risk of AMR emergence and transmission to humans and the environment. Projects can analyse how mechanisms of action, formulations, routes of administration and dosing regimens of antibacterial and antifungal products affect resistance development and spread. They should also propose improvements to formulations, dosages and treatment regimens that reduce cross‑resistance or transmission risk and support policies that restrict certain antimicrobials for exclusive human use, in line with instruments such as the WHO List of Medically Important Antimicrobials.

Across all topics, proposals must explicitly consider how their approach impacts the risk of resistance in other One Health settings and how it could be extended to additional settings beyond the initial focus. Proposals must show a realistic and feasible plan, with clear objectives, a robust methodology, a detailed workplan, risk identification and mitigation, and appropriate allocation of resources. The consortium must demonstrate that transnational collaboration adds clear value, for example by sharing expertise, data, models, samples or technologies, and by harmonising approaches between countries. In addition, proposals must clearly describe the expected health, social and/or economic impacts and explain how project results will be taken up by end‑users, policy‑makers, industry, or the next actors in the value chain.

Participation of the private sector (start‑ups, SMEs and industry) is encouraged where it fits the project objectives and is allowed by national funding rules. All pre‑proposals and full proposals must be written in English and follow the required template format; proposals that do not respect formal requirements (length of sections, number of CVs, letters of intent, etc.) can be rejected without further review.

How to apply:

• Build a transnational consortium with partners from at least two different participating countries, ensuring that each partner is eligible and funded by its own national organisation.
• Read the full call text, participating country list, and national rules and requirements on the EUP OHAMR call website.
• Identify which one of the three topics (Topic 1, Topic 2 or Topic 3) your project will address and define a clear One Health scope (human, animal, plant, environment).
• Prepare a pre‑proposal in English using the official EUP OHAMR pre‑proposal template. The coordinator submits this via the EUP OHAMR electronic submission platform by the pre‑proposal deadline.
• Check whether your national funding organisation requires parallel submission on its platform and submit any additional national forms by the relevant deadlines.
• If invited, develop a full proposal, again in English and following the official full‑proposal template, expanding on the scientific plan, management, impact and budget details.
• Ensure all partners comply with both the joint call rules and the specific eligibility, cost and reporting rules of their national funders.

Readers should understand that this is a competitive, two‑stage, international call where success depends on building a strong, complementary consortium; choosing one of the three topics; designing a scientifically sound and feasible project; and clearly demonstrating how the proposed work will improve treatment outcomes and reduce AMR risk in One Health systems.

Who should apply (target applicants):

• Universities and public research organisations
• Hospitals, clinical research centres and public health institutes
• Veterinary and agricultural research institutes
• SMEs, start‑ups and industry (where allowed by national rules)
• Multi‑partner consortia with expertise in microbiology, infectious diseases, pharmacology, behavioural science, digital health, veterinary medicine, plant health, epidemiology, policy and related fields

Funding amount and duration:

• Total indicative call budget: over €31 million
• Grant form: project grants funded by national/regional agencies for their own partners
• Maximum project duration: up to 3 years
• Exact funding available per partner depends on national funding organisation rules

Key dates:

• Call opens: 18 November 2025
• Pre‑proposal deadline: 2 February 2026 (time as specified in call text)
• Full‑proposal deadline: to be confirmed in the call timetable for invited consortia
• Expected project start: after evaluation and national funding decisions (see call website)

Location / participating countries:
28 participating countries from Europe and beyond, including (among others): Austria, Belgium, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Slovakia, South Africa, Spain, Sweden, Switzerland, Türkiye and the United Kingdom. Each country participates through one or more national funding organisations.

Contact details / where to find more information:

• EUP OHAMR Joint Transnational Call 2026 main page: https://ohamr.eu/calls/call-2026-new-treatments-to-tackle-amr/
• National rules and contact points: https://ohamr.eu/calls/call-2026-new-treatments-to-tackle-amr/jtc-2026-national-rules-and-requirements/
• Electronic submission platform: linked from the main call page
• Applicants should contact their national/regional funding organisation for eligibility and budget questions.